"Quinacrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
| Descriptor ID |
D011796
|
| MeSH Number(s) |
D03.633.300.046.250.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinacrine".
Below are MeSH descriptors whose meaning is more specific than "Quinacrine".
This graph shows the total number of publications written about "Quinacrine" by people in this website by year, and whether "Quinacrine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinacrine" by people in Profiles.
-
Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties. Oncotarget. 2016 Aug 16; 7(33):52928-52939.
-
Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016 Apr 01; 105:23-33.
-
Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis. 2013 Feb; 34(2):277-86.
-
Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer. 2012 Apr 01; 130(7):1660-70.
-
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
-
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
-
Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization. J Pharmacol Exp Ther. 1996 Mar; 276(3):1244-56.